ALK相关资料汇总（更新于2020.7.7）
ALK抑制剂耐药的分子机制和对策https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=28535&extra=page%3D2%26filter%3Dauthor%26orderby%3DdatelineALK靶向药物（二）常见不良反应和处理https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=29619&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
ALK二次突变的演化规律https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58617&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
ALK TKI耐药后的基因检测https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58651&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
不同ALK融合亚型与临床疗效的关系https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58653&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
ALK/EGFR和ALK/KRAS双突变NSCLC https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59253&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
ALK融合阳性NSCLC的耐药对策https://mp.weixin.qq.com/s/PY9fJs3B2r6uj5Zr5GZiHw
ROS1阳性NSCLC靶向治疗进展https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58654&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
NGS跟踪ALK抑制剂的耐药演变https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59265&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
二代ALK抑制剂耐药后培美曲赛方案的疗效https://mp.weixin.qq.com/s/w3gJ72RSPEKk2VJi7fb6rA
具体分类（按药物）克唑替尼=赛可瑞=Crizotinib（第一代）
克唑替尼和阿法替尼的剂量调整https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=29620&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
克唑替尼对ALK阳性NSCLC患者脑转移的疗效https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58618
克唑替尼(赛可瑞)使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58827&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
克唑替尼耐药后，28位美国医生的临床决策https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59251&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
克唑替尼治疗ROS1/ALK融合阳性NSCLC的临床差异https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59259&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布格替尼（布加替尼）=AP26113=brigatinib（Alunbrig）（第二代）
Brigatinib（AP26113）简介https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=30045&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
AZD9291耐药新出路：AP26113联合爱必妥的逆袭？！https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=36169&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
布格替尼（AP26113）的新剂量爬坡方案https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75375&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布格替尼（AP26113）联合司美替尼克服C797S突变导致的奥希替尼耐药https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75377&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布格替尼治疗阿来替尼耐药后的ALK阳性NSCLC https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75376&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布格替尼（Brigatinib）批准用于一线治疗ALK阳性转移性NSCLC https://mp.weixin.qq.com/s/FMMaRnnYmA4nZzLErDlR0Q
Alunbrig（Brigatinib）美国FDA版说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59252&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布加替尼Brigatinib与间质性肺炎https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59255&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
Alunbrig（Brigatinib）美国FDA版说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75337&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布加替尼Brigatinib与间质性肺炎https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75370&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
关于Brigatinib联合爱必妥方案的几个关键问题https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75378&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
色瑞替尼（赛瑞替尼）= ceritinib= LDK378（第二代）
色瑞替尼给药方案调整https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58652&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
色瑞替尼使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58826&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
色瑞替尼减量随餐服用可减少胃肠道副作用https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59264&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
色瑞替尼治疗脑转移ALK阳性NSCLC https://mp.weixin.qq.com/s/g6NA0VrHV6rTrDrghoV0aA
赛瑞替尼治疗ALK阳性脑膜转移NSCLC https://mp.weixin.qq.com/s/QQwZY8Dg4V63iIbBu3rHUg
阿来替尼=Alectinib（第二代）
Alectinib成为ALK阳性肺癌一线新霸主https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=42231
阿来替尼治疗ALK阳性脑转移NSCLC https://mp.weixin.qq.com/s/FR-j9nnVZI0s51o4bXhaYw
劳拉替尼（洛拉替尼）= Lorlatinib（第三代）
Lorlatinib（PF-06463922）简介https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=30046&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
洛拉替尼Lorlatinib耐药机制（ALK部分）https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59254&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
洛拉替尼的耐药机制https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59287&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
第三代ALK抑制剂Lorlatinib日本批准上市！https://mp.weixin.qq.com/s/31bc0c-abxJF6kFvOqrV_A
洛拉替尼Lorlatinib的特有副作用和处置https://mp.weixin.qq.com/s/aqvGu8Xv8d12s7RSaIeEFg
1-2代ALK抑制剂逆转Lorlatinib耐药？https://mp.weixin.qq.com/s/mCtGlBWWwq2Q02UHD-M88g
【ESMO 2017】Lorlatinib治疗ROS1阳性NSCLC https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59260&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
恩莎替尼= Ensartinib=X-396（第三代）
深入解析Ensartinib（X-396）https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=35573&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
恩莎替尼（Ensartinib，X-396）的ALK耐药突变https://mp.weixin.qq.com/s/naKJTyNXJrzEKpXXyC1Inw
新一代ALK抑制剂Ensartinib（X-396）https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=28490&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
X-396治疗ALK阳性脑转移NSCLC https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59250&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
恩曲替尼= Entrectinib（第三代）
ROS1/ALK/TRK新药:Entrectinib https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58621&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
恩曲替尼Entrectinib日文版说明书翻译https://mp.weixin.qq.com/s/i0ee8Ahw0GC611j-eLVGPA
洛普替尼 =TPX-0005= Repotrectinib
ALK四代药TPX-0005要来了https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59137&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
【ASCO2018】洛普替尼TPX-0005一期临床进展https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59288&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
洛普替尼TPX-0005一期临床进展https://mp.weixin.qq.com/s/OpLWORojzcRe2skvq9-8UA
塞卡替尼=Saracatinib=AZD0530
Saracatinib（AZD0530）的新用途https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58616&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
AZD0530的剂量和副作用https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59134&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
其他：
卡博替尼使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58828&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
布吉他滨使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58829&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
艾乐替尼使用说明书https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58835&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
一些病例与临床数据：
【ALK+NSCLC】小6的治疗史https://mp.weixin.qq.com/s/-CMI8ZpEJaSs_5UsMbgrww
第四代ALK抑制剂TPX-0131临床前数据！https://mp.weixin.qq.com/s/j6kkIZJzVv9YTkJvmi4RoA
BRIGALK研究：中位总生存期75个月！https://mp.weixin.qq.com/s/xVf8GPlXz1TscZhwkyaNOw
ALK阳性脑膜转移实例https://mp.weixin.qq.com/s/-uBXoyY8Sm2TOnvN3IxvJg
【ELCC2019】布格替尼（AP26113）真实世界数据https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=75379&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
【AACR2018】洛拉替尼Lorlatinib数据更新https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59286&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
新一代ALK抑制剂Ensartinib（X-396）2期临床数据解读https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=58615&extra=page%3D2%26filter%3Dauthor%26orderby%3Ddateline
洛拉替尼二期临床数据解读https://www.yuaigongwu.com/forum.php?mod=viewthread&tid=59257&extra=page%3D1%26filter%3Dauthor%26orderby%3Ddateline
克唑替尼逆转洛拉替尼耐药一例https://mp.weixin.qq.com/s/7SAR2NaHjdrURI-4tqtIcw
塞瑞替尼逆转洛拉替尼耐药一例https://mp.weixin.qq.com/s/2Wl0a7ikeUfMUPstTUXZGw
页:
[1]